法维皮拉维
偏肺病毒
鼻病毒
抗病毒药物
病毒
病毒学
医学
药品
变性肺病毒
药理学
呼吸道感染
呼吸系统
2019年冠状病毒病(COVID-19)
疾病
内科学
传染病(医学专业)
作者
Julia M Smyk,Anna Majewska
出处
期刊:Mini-reviews in Medicinal Chemistry
[Bentham Science]
日期:2022-09-01
卷期号:22 (17): 2224-2236
被引量:6
标识
DOI:10.2174/1389557522666220218122744
摘要
Among antiviral drugs, the vast majority targets only one or two related viruses. The conventional model, one virus - one drug, significantly limits therapeutic options. Therefore, in the strategy of controlling viral infections, there is a necessity to develop compounds with pleiotropic effects. Favipiravir (FPV) emerged as a strong candidate to become such a drug. The aim of the study is to present up-to-date information on the role of favipiravir in the treatment of viral respiratory infections. The anti-influenza activity of favipiravir has been confirmed in cell culture experiments, animal models, and clinical trials. Thoroughly different - from the previously registered drugs - mechanism of action suggests that FVP can be used as a countermeasure for the novel or re-emerging influenza virus infections. In recent months, favipiravir has been broadly investigated due to its potential efficacy in the treatment of COVID-19. Based on preclinical and clinical studies and a recently published meta-analysis it seems that favipiravir may be a promising antiviral drug in the treatment of patients with COVID-19. FPV is also effective against other RNA respiratory viruses and may be a candidate for the treatment of serious infections caused by human rhinovirus, respiratory syncytial virus, metapneumovirus, parainfluenza viruses and hantavirus pulmonary syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI